On April 22, 2025 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, reported that data from 8 studies will be shared at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting that will take place April 25 – 30, 2025 in Chicago, IL (Press release, Natera, APR 22, 2025, View Source [SID1234652026]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Highlights from AACR (Free AACR Whitepaper) include:
An oral presentation titled "Large-scale Genomic Profiling of Colorectal Cancer" from an exploratory analysis examining the characteristics of the mutational landscape of CRC and patterns across clinical and molecular subgroups. The study was performed using Natera’s proprietary real-world database (RWD) that comprises de-identified clinical and genomic data from over 73,000 patients who underwent commercial Signatera testing.
Poster presentations exploring the genomic landscape in over 30,000 breast cancer patients and over 8,000 gynecologic cancer patients, revealing distinct genomic patterns, and underscoring the research value of Natera’s RWD.
Data that integrates Natera’s clinical and genomic information, demonstrating how its real-world evidence database can enhance immunotherapy response prediction by improving neoantigen identification.
Further datasets in esophageal cancer, sarcoma, and CRC, adding to the evidence base of Signatera’s clinical validity and utility.
"We are pleased to share such a broad set of data showcasing our breadth of capabilities in oncology," said Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer. "In addition to presenting Signatera data in several types of cancer, we look forward to presentations that leverage the use of our multi-modal database of real-world evidence, which can provide valuable insights to strengthen drug discoveries and potentially accelerate therapeutic breakthroughs."
About Signatera
Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. The test is available for clinical and research use and has coverage by Medicare across a broad range of indications. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 100 peer-reviewed papers.